Clinical study
Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)

https://doi.org/10.1016/0002-9343(72)90064-2Get rights and content

Abstract

We describe the clinical and serologic findings in twenty-five patients with an apparently distinct rheumatic disease syndrome which we have termed mixed connective tissue disease. All these patients had hemagglutinating antibody to an extractable nuclear antigen (ENA) which consists mainly of protein and ribonucleic acid (RNA). A marked sensitivity of the hemagglutination antigen to ribonuclease indicated that the specificity of the antibody to ENA circulating in these patients was different from that of antibody to ENA which occurred in about 50 per cent of the patients with systemic lupus erythematosus. Serum from patients with mixed connective tissue disease also contained high titers of speckled pattern fluorescent antinuclear antibody which showed the same response of tissue antigens to enzyme digestion as found with hemagglutinating antibody. There was no detectable Sm antibody. Antibody to native deoxyribonucleic acid (DNA) was infrequent and of low titer, and serum complement levels were normal or elevated.

The clinical characteristics of the patients with mixed connective tissue disease included a combination of features similar to those of systemic lupus erythematosus, scleroderma and polymyositis. Most of these abnormalities were responsive to corticosteroid therapy.

Thus, the detection of antibody to ENA with a well defined specificity allows recognition of an apparently distinct mixed connective tissue disease syndrome which is characterized by an excellent response to corticosteroid therapy and a favorable prognosis.

References (39)

  • EM Tan

    Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus

    J Lab Clin Med

    (1967)
  • EM Tan et al.

    An immunofluorescent study of the skin lesions in systemic lupus erythematosus

    Arthritis Rheum

    (1966)
  • EM Tan et al.

    Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus

    J Clin Invest

    (1966)
  • EM Tan et al.

    Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus

    J Immun

    (1966)
  • HR Holman et al.

    The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucieoprotein of the cell nucleus

    J Clin Invest

    (1959)
  • EA Kabat et al.

    Experimental Immunochemistry

  • LD Petz et al.

    Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus

    Medicine

    (1971)
  • GP Rodnan

    Progressive systemic sclerosis (diffuse scleroderma)

  • DL Tuffanelli et al.

    Systemic scleroderma

    Arch Derm (Chicago)

    (1961)
  • Cited by (0)

    This work was supported in part by U.S. Public Health Service Research Grant No. AM-05425 from the National Institute of Arthritis and Metabolic Diseases and by Grant No. FR-70 from the General Clinical Research Centers Branch, Division of Research Facilities and Resources, National Institutes of Health, Bethesda, Maryland.

    Present address: Division of Immunology and Rheumatology, Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65201.

    1

    From the Department of Medicine, Stanford University School of Medicine, Stanford, California 94305.

    3

    From the Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri 65201.

    2

    From the Division of Allergy and Immunology, Scripps Clinic and Research Foundation, La Jolla, California 92037.

    View full text